Diagnosis & Disease Information

Adding Galunisertib to Gemcitabine Improves OS, PFS in Pancreatic Cancer

By

Jason Hoffman, PharmD, RPh

April 20, 2016

The addition of galunisertib to gemcitabine demonstrated improved overall and progression-free survival in pancreatic cancer.

CTA asked Dr. Patnaik about the evolving understanding of CMML’s molecular underpinnings, diagnosis,

Anti-CD19 CAR T-Cells Safe for Refractory Aggressive Non-Hodgkin Lymphoma

By

Jason Hoffman, PharmD, RPh

April 20, 2016

Anti-CD19 chimeric antigen receptor (CAR) T-cells were determined to be safe for further study in patients with refractory aggressive non-Hodgkin lymphoma.

While researchers seek better methods to preserve ovarian function, new tools are being developed to

Neoadjuvant T-DM1 Plus Pertuzumab May Improve HER+ Breast Cancer Outcomes

By

Jason Hoffman, PharmD, RPh

April 20, 2016

Neoadjuvant ado-trastuzumab emtansine (T-DM1) combined with pertuzumab substantially improved pathologic complete response rates.

Men whose castration-resistant prostate cancer has metastasized to the liver have the worst overall

Labetuzumab Govitecan Active in Heavily Pretreated mCRC

By

Jason Hoffman, PharmD, RPh

April 20, 2016

Monotherapy with labetuzumab govitecan is active in heavily pretreated patients with metastatic colorectal cancer (mCRC).

Sunitinib represents an acceptable option in first line treatment for mPRCC.

Entinostat May Improve Benefit of High-dose IL-2 in RCC

By

Jason Hoffman, PharmD, RPh

April 19, 2016

Entinostat may synergistically improve the therapeutic effect of high dose interleukin-2 (IL-2) in treatment-naïve clear cell renal cell carcinoma (RCC).

The use of combination aromatase inhibitors with bisphosphonates could help reduce breast cancer mor

Crizotinib Active in MET+ Papillary mRCC Type 1

By

Jason Hoffman, PharmD, RPh

April 19, 2016

Crizotinib induces objective responses and long-lasting disease control in metastatic papillary renal cell carcinoma type 1 (PRCC1).

Early individualization of the dosage of imatinib may optimize outcomes in chronic phase chronic mye

Study Assesses Mechanisms Behind Ibrutinib Resistance in CLL

By

Jason Hoffman, PharmD, RPh

April 19, 2016

Most patients with progressive chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy harbor BTK and/or PLCG2 mutations.

An analysis has confirmed that 2013 European LeukaemiaNet (ELN) response categories can reliably pre

PD-L1 Positivity Associated With Improved Efficacy of Pembrolizumab vs Ipilimumab

By

Jason Hoffman, PharmD, RPh

April 19, 2016

Programmed death-ligand 1 (PD-L1) positivity is associated with improved efficacy with pembrolizumab in patients with advanced melanoma.

Biochemotherapy Shows Benefits in High-Risk Melanoma, But Newer Agents Will Get More Use

Pembrolizumab Resulted in Durable Responses in Advanced Merkel Cell Carcinoma

By

Jason Hoffman, PharmD, RPh

April 19, 2016

First-line therapy with pembrolizumab yielded frequent and durable response in patients with advanced Merkel cell carcinoma.

Hand holding pill

Nivolumab Improves Survival in Head and Neck Cancer

By

Jason Hoffman, PharmD, RPh

April 19, 2016

Nivolumab improved overall survival in patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Next post in AACR 2016

Patients with early breast cancer experienced a pathologic complete response rate with nab-paclitaxe

Nivolumab Monotherapy Induces Durable, Long-term Survival in Advanced Melanoma